Cardio. MMVD. Chap 48 Flashcards

1
Q

incidence

A
  • approximately 10% of dogs presented to primary care veterinary practices have heart disease
  • MMVD is the most common approximately 75% in NA
  • small breed dogs, with up to 85% showing evidence of the valve lesion by 13 years of age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

most commonly affects MV, ____% TV:
males vs females:
large vs small:
inheritied and genetic component in some breeds

A

30%
1.5X more common in males
large dogs have faster progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pathophys. disease consistently is characterized by:

A
  • changes in collagen and alignment of collagen fibrils within the valve
  • changes in the proteoglycan content = expansion of the spongiosa layer
  • activated myofibroblasts & matrix metalloproteinases, which degrade collagen and elastin faster than they can be produced
  • hypothesized that abnormal numbers or types of mitogen receptors (ie, any of the subtypes of serotonin, endothelin, or angiotensin receptors) on fibroblast cell membranes in the valves of affected dogs play a role in the pathophysiology of acquired valvular lesions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

increased risk of sequelea?

A

no, no increased risk of PTE or infective endocarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathopys. leading to CHF

A
  • progressive deformation of the valve structure
  • prevents effective coaptation, allowing regurgitation
  • valvular regurgitation increases cardiac work = ventricular remodeling (eccentric hypertrophy of both the atrium and ventricle, and intercellular matrix changes)
  • eventually to ventricular dysfunction - volume overload and CHF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What factors are moderately predictive of the rate of progression of MMVD and can help identify dogs at risk for impending heart failure:

A
  • progressive heart enlargement (of the left atrium [LA] and ventricle)
  • increased transmitral E wave blood flow velocities
  • increased serum NT‐proBNP
  • increases in resting HR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define “heart failure”:

A

“heart failure” refers to CS caused by heart dysfunction.

  • such that either venous pressures increase so severely that fluid accumulates in the lungs or a body cavity (congestive heart failure [CHF]/ “backward” failure)
  • pumping ability is compromised such that it cannot meet the body’s, in the face of either normal or increased venous pressures (sometimes called “forward heart failure”)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

2009 consensus:

staging system for MMVD describes 4 basic stages

staging system, applied to dogs with MMVD, remains useful, although recent clinical trial results necessitate a more critical clinical evaluation of dogs in Stage B to facilitate sound therapeutic decision making

A

Stage A: identifies dogs at high risk but no identifiable structural disorder (eg, every Cavalier King Charles)

Stage B: identifies dogs with structural heart disease (eg, the typical murmur), never developed clinical signs

Stage B1

  • asymptomatic dogs that have no radiographic or echocardiographic evidence of cardiac remodeling
  • as well as those in which remodeling changes are present, but not severe enough to meet current clinical trial criteria that have been used to determine that initiating treatment is warranted

Stage B2
-asymptomatic dogs w more advanced mitral valve regurgitation caused radiographic and echo findings of left atrial and ventricular enlargement that meet clinical trial criteria that clearly should benefit from initiating pharmacologic treatment

Stage C denotes dogs with either current or past clinical signs of heart failure caused by MMVD.

Stage D end‐stage MMVD, clinical signs of heart failure are refractory to standard treatment (defined later in this consensus statement). Such patients require advanced or specialized treatment strategies to remain clinically comfortable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

In a change from the 2009 recommendations:

A

strong evidence now supports initiating treatment to delay the onset of clinical signs of heart failure at stage B2 patients with more advanced cardiac morphologic changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diagnostic and theraputic guidelines/ stage:

Stage A:

A

unchanged from 2009 - 2019 consensus

  • predisposed breeds (eg, Cavalier King Charles Spaniels, Dachshunds, Miniature, and Toy Poodles)
  • yearly auscultation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnostic and theraputic guidelines/ stage:

Stage B:

A

unchanged from 2009 - 2019 consensus

Dx: baseline radiographs, BP, echo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnostic and theraputic guidelines/ stage:

Stage B1:

A

unchanged from 2009 - 2019 consensus
Dx: baseline radiographs, BP, echo
Tx: not recommended
Reeval: echo (or radiography) in 6‐12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diagnostic and theraputic guidelines/ stage:
Stage B2:
Stage B2 criteria for treatment before the onset CHF: (Class I, LOE: Strong):

In the absence of echocardiographic measurements…

A

Stage B2 criteria for treatment before the onset CHF: (Class I, LOE: Strong):

  • murmur intensity ≥3/6;
  • echocardiographic LA : Ao ratio in the right‐sided short axis view in early diastole ≥1.6
  • Left ventricular internal diameter in diastole, normalized for body weight (LVIDDN) ≥1.7
  • vertebral heart score (VHS) >10.5.

..clear radiographic evidence of cardiomegaly (eg, a “general breed” VHS ≥11.5, or a comparable “breed‐adjusted” VHS in cases where breed‐specific VHS normal values are available) or evidence of accelerating (increasing) interval change in radiographic or echocardiographic cardiac enlargement patterns can substitute for quantitative echocardiography to identify Stage B2. (Class I, LOE: expert opinion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

newer index of radiographic left atrial enlargement:

explain how to perform it and what normal is:

A

VLAS (vertebral LA size) - quantitative method of estimating left atrial size

  • right or left lateral radiograph
  • line from the center/ventral carina
  • to most caudal aspect of the LA
  • intersects with the dorsal border of the caudal vena cava,
  • line then is transposed to the cranial edge of the 4th thoracic vertebral body

-Studies are ongoing to determine a VLAS value that accurately predicts B2 remodeling, but in the absence of echocardiography, VLAS values of ≥3 likely identify Stage B2 MMVD. (Class 1, LOE: moderate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stage B2 treatment:

A

Pimobendan -0.25‐0.3 mg/kg PO q12h (Class I, LOE: strong)

Mild dietary sodium restriction and provision of a highly palatable diet with adequate protein and calories (Class IIa, LOE: weak)

ACEI on either initial examination, or in which the LA has increased markedly in size on successive monitoring examinations, 5 (of 10) panelists recommend treatment with ACEI (LOE: weak)
Clinical trials addressing the efficacy of ACEI for treatment of dogs in Stage B have shown mixed results

+/- cough suppressants - when their cough is thought to be the result of pressure from cardiac enlargement on adjacent bronchi. (Class IIa, LOE: expert opinion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Logistical difficulties associated with the stability of B-type natriuretic peptide have been overcome with pro-BNP:
What is it?
What other factors influence it?

A

more stable amino terminal portion of the cleaved pro-hormone (NT-proBNP)
These assays have been validated and demonstrate
good sensitivity and specificity in differentiating patients with dyspnea secondary to cardiac disease versus primary respiratory

numerous other factors e.g., pulmonary hypertension, renal dysfunction

17
Q

What is P mitrale
P pulmonale
ECG evidence of left ventricular enlargement

A

P wave width >40 msec
P wave height >0.5 mV
evidence of left ventricular enlargement = R wave amplitude >2.5 mV or duration >60 msec

18
Q

Describe radiographic finding of MMVD

A
  • loss of the caudal cardiac waist (left atrial enlargement)
  • tall cardiac silhouette (left ventricular enlargement)
  • dorsal deviation of the trachea
  • pulmonary venous congestion in cranial lobar veins on the lateral projection and caudal lobar veins on the orthogonal projection
  • dorsoventral better visualization of the caudal pulmonary vasculature and is less stressful
  • severe TR: changes consistent with right-sided heart enlargement (reverse D on dorsoventral films, increased sternal contact)
  • global or generalized cardiomegaly

-pulmonary edema mild, perihilar, or central
interstitial infiltrate. As the severity of the infiltrates increases in

heart failure or biventricular disease, pleural fissure lines or overt effusion may be visible and there may be a loss of serosal detail in
the abdomen.

19
Q

Classic echo fingings

A

left ventricular and left atrial dilation
hyperdynamic left ventricular wall motion
and thickened mitral valve leaflets

20
Q

Diagnosing Stage C:

S and PE plus labs:

A
  • obese dogs with no history of weight loss
  • marked sinus arrhythmia and relatively slow heart rates = less likely to have clinical signs attributable to MMVD
  • BW, radiographs, echo., proBNP
21
Q

Diagnosing Stage C:
benefit of echo:
comorbidities:

A
  • confirm the presence of MMVD
  • quantify chamber enlargements and cardiac function,
  • estimates of LV filling pressures
  • identify comorbidities and complications of chronic MR
  • pulmonary hypertension, acquired atrial septal defect, and pericardial effusion from an atrial tear or unrelated cardiac tumor
  • i.e. pretreatment finding of a low‐velocity E‐wave on pulsed‐wave Doppler strongly argues against a diagnosis of left‐sided heart failure
  • Conversely, most dogs in Stages C and D have high‐velocity early filling waves
22
Q

normal or near normal NT‐proBNP

A

normal or near normal NT‐proBNP concentration in a dog with clinical signs of cough, dyspnea, or exercise intolerance strongly suggests that heart failure is not the cause of the clinical signs

23
Q

Acute Stage C tx:

A
  1. Furosemide 2 mg/kg administered IV (or intramuscularly [IM]), followed by 2 mg/kg IV or IM hourly until the patient’s respiratory signs are substantially improved
    - or total dosage of 8 mg/kg has been reached over 4 hours. (Class I, LOE: expert opinion)
  2. life‐threatening pulmonary edema (ie, expectoration of froth associated with severe dyspnea, radiographic white‐out lung, poor initial response to furosemide over 2 hours), furosemide also may be administered as a CRI 0.66‐1 mg/kg/hour after the initial bolus (Class IIa, LOE: weak)

***Allow the patient free access to water once diuresis has begun. (Class I, LOE: expert opinion; humane considerations apply)

  1. Pimobendan, 0.25‐0.3 mg/kg administered PO q12h. Although the clinical trial evidence supporting the chronic use of pimobendan in the management of Stage C heart failure from MMVD is stronger than for the acute presentation, the recommendation to use pimobendan in acute heart failure treatment is strongly supported by hemodynamic and experimental evidence as well as the anecdotal experience of the panelists
    - outside of the United States, pimobendan for IV administration is available. (Class I, LOE: weak)
  2. Oxygen supplementation
  3. Sedation‐anxiety with dyspnea should be treated Butorphanol 0.2 to 0.25 mg/kg administered IM or IV was the narcotic most often utilized for this purpose; combinations of buprenorphine (0.0075‐0.01 mg/kg) and acepromazine (0.01‐0.03 mg/kg IV, IM, or SC) (Class I, LOE: expert opinion)

Provide optimal nursing care, patients in sternal posture.

  1. Dobutamine (2.5‐10 μg/kg/min as a CRI, starting at 2.5 μg/kg/min and increasing the dosage incrementally) may be used in addition to the above treatments to improve the left ventricular function in patients that fail to respond adequately to diuretics, pimobendan, sedation, oxygen, and comfort care measures.

Continuous ECG monitoring is recommended where available during dobutamine infusion, with dosage reduction indicated if tachycardia or ectopic beats occur. (Class I, LOE: expert opinion)

24
Q

When to consider nitroprusside:

A

CRI sodium nitroprusside 1 to 15 μg/kg/min for up to 48 hrs useful for life‐threatening, poorly responsive pulmonary edema

this medication is currently (2018) expensive
PO titration of additional arterial dilators (eg, hydralazine or amlodipine, specific dosing recommendations also in Class D below) also may be useful in patients when administration of nitroprusside is not feasible. (Class I, LOE: weak)
ACEI, for example, enalapril or benazepril, 0.5 mg/kg PO q12h. Although treatment with an ACEI is a Class I recommendation for chronic Stage C heart failure (see below) and some panelists also treat acute heart failure with ACEI, the evidence supporting ACEI efficacy and safety in acute treatment, when combined with furosemide and pimobendan, is less clear. There is, however, clear evidence that the acute administration of enalapril plus furosemide in acute heart failure results in significant improvement in pulmonary capillary wedge pressure when compared with the administration of furosemide alone.70 (Class IIb, LOE: weak)
Nitroglycerin ointment, approximately half an inch paste/10 kg BW, applied to an unhaired or shaved area of skin, can be used for the first 24 to 36 hours of hospitalization.71, 72 Some panelists recommend administering the ointment at intervals (12 hours on, 12 hours off). Other panelists do not use nitroglycerin in this setting. (Class IIb, LOE: weak)